Ananda Pharma completes dosing in phase 1 trial of CBD formulation
PositiveFinancial Markets

Ananda Pharma has successfully completed dosing in its phase 1 trial of a new CBD formulation, marking a significant step forward in the development of cannabinoid-based therapies. This trial is crucial as it assesses the safety and tolerability of the formulation, which could pave the way for future treatments in various medical conditions. The completion of this phase not only highlights Ananda Pharma's commitment to innovation but also brings hope to patients seeking alternative therapies.
— Curated by the World Pulse Now AI Editorial System